Pharmaceutical Giants Unite to Boost AI-Driven Drug Discovery
2 Sources
2 Sources
[1]
Bristol Myers, Takeda to pool data for AI-based drug discovery
Oct 1 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab, Takeda Pharmaceuticals (4502.T), opens new tab and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and development. The companies are joining a consortium that includes AbbVie (ABBV.N), opens new tab and Johnson & Johnson <JNJ.N>, and will contribute data from several thousand experimentally determined protein-small molecule structures to train an AI model called OpenFold3, life sciences company Apheris said on Wednesday. The initiative is based on a federated data sharing model, which enables collaboration without exposing sensitive data. Germany-based Apheris' computing platform enables the aggregation of diverse data sets from companies while ensuring each dataset remains securely in its original location. By pooling these datasets, the initiative aims to improve OpenFold3's accuracy in predicting interactions of proteins and small molecules. The federated platform allows multiple companies to "advance predictive models for small molecule discovery in ways no single organization could achieve alone," said Payal Sheth, vice president, discovery biotherapeutics and lead discovery and optimization at Bristol. OpenFold3 is the flagship project of the industry-led AI Structural Biology Network, conducted in collaboration with the AlQuraishi Lab at Columbia University. This consortium really ties into our larger corporate goal of embedding AI throughout all of what we do; and also a nice example of how we can come together as pharma companies and do even more for patients than we could if we did it on our own, said Hans Bitter, head of computational sciences at Takeda. Reporting by Sneha S K in Bengaluru; Editing by Sahal Muhammed Our Standards: The Thomson Reuters Trust Principles., opens new tab
[2]
Bristol Myers, Takeda to pool data for AI-based drug discovery
(Reuters) -Bristol Myers Squibb, Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and development. The companies are joining a consortium that includes AbbVie and Johnson & Johnson, and will contribute data from several thousand experimentally determined protein-small molecule structures to train an AI model called OpenFold3, life sciences company Apheris said on Wednesday. The initiative is based on a federated data sharing model, which enables collaboration without exposing sensitive data. Germany-based Apheris' computing platform enables the aggregation of diverse data sets from companies while ensuring each dataset remains securely in its original location. By pooling these datasets, the initiative aims to improve OpenFold3's accuracy in predicting interactions of proteins and small molecules. The federated platform allows multiple companies to "advance predictive models for small molecule discovery in ways no single organization could achieve alone," said Payal Sheth, vice president, discovery biotherapeutics and lead discovery and optimization at Bristol. OpenFold3 is the flagship project of the industry-led AI Structural Biology Network, conducted in collaboration with the AlQuraishi Lab at Columbia University. This consortium really ties into our larger corporate goal of embedding AI throughout all of what we do; and also a nice example of how we can come together as pharma companies and do even more for patients than we could if we did it on our own, said Hans Bitter, head of computational sciences at Takeda. (Reporting by Sneha S K in Bengaluru; Editing by Sahal Muhammed)
Share
Share
Copy Link
Bristol Myers Squibb, Takeda, and others join forces to share proprietary data for training an AI model, aiming to revolutionize drug discovery and development processes.
Pharmaceutical Collaboration for AI-Driven Drug Discovery
In a groundbreaking move, major pharmaceutical companies are joining forces to accelerate drug discovery and development through artificial intelligence. Bristol Myers Squibb, Takeda Pharmaceuticals, and Astex Pharmaceuticals have announced their participation in a consortium that includes industry giants AbbVie and Johnson & Johnson
1
. This collaborative effort aims to harness the power of AI to revolutionize the drug discovery process.The OpenFold3 AI Model
The centerpiece of this initiative is an AI model called OpenFold3, which will be trained on a vast array of proprietary data contributed by the participating companies. Specifically, the consortium members will share data from several thousand experimentally determined protein-small molecule structures
2
. By pooling these extensive datasets, the initiative seeks to enhance OpenFold3's accuracy in predicting interactions between proteins and small molecules, a crucial aspect of drug discovery.Federated Data Sharing: Balancing Collaboration and Security
A key feature of this collaboration is the use of a federated data sharing model. This innovative approach allows companies to work together without exposing sensitive proprietary information. Germany-based life sciences company Apheris provides the computing platform that enables this secure collaboration
1
.Payal Sheth, Vice President of Discovery Biotherapeutics and Lead Discovery and Optimization at Bristol Myers Squibb, highlighted the significance of this approach: "The federated platform allows multiple companies to advance predictive models for small molecule discovery in ways no single organization could achieve alone"
2
.Industry-Wide AI Integration
This consortium is part of a broader trend in the pharmaceutical industry to integrate AI across all aspects of drug development. Hans Bitter, Head of Computational Sciences at Takeda, emphasized this point, stating, "This consortium really ties into our larger corporate goal of embedding AI throughout all of what we do"
1
.Related Stories
Collaboration for Patient Benefit
The initiative not only showcases the potential of AI in drug discovery but also highlights the power of collaboration in the pharmaceutical industry. Bitter noted that this partnership is "a nice example of how we can come together as pharma companies and do even more for patients than we could if we did it on our own"
2
.The AI Structural Biology Network
OpenFold3 is the flagship project of the industry-led AI Structural Biology Network. This network is conducting its research in collaboration with the AlQuraishi Lab at Columbia University, further emphasizing the intersection of industry and academic expertise in this cutting-edge field
1
.References
Summarized by
Navi
[2]
Related Stories
Weekly Highlights
Weekly Highlights
Today's Top Stories
Your Daily Dose of Curated AI News
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.
